efavirenz

efavirenz is a medication used in combination with other antiretroviral drugs to treat HIV/AIDS, as recommended by the World Health Organization and the Centers for Disease Control and Prevention. It is often used in combination with tenofovir and emtricitabine, as part of a regimen known as Atripla, which is manufactured by Gilead Sciences and Bristol-Myers Squibb. The use of efavirenz has been endorsed by UNAIDS, the Joint United Nations Programme on HIV/AIDS, and the National Institutes of Health.

● Introduction

efavirenz was first approved by the US Food and Drug Administration in 1998, and has since become a key component of antiretroviral therapy regimens, as recommended by the European AIDS Clinical Society and the International AIDS Society. It is marketed by Bristol-Myers Squibb under the brand name Sustiva, and is also available in generic form from manufacturers such as Cipla and Myanmar Pharmaceutical Industries. The development of efavirenz was supported by research conducted at institutions such as the University of California, San Francisco and the Massachusetts Institute of Technology, and was influenced by the work of scientists such as David Ho and Eric Lander.

● Mechanism_of_action

The mechanism of action of efavirenz involves the inhibition of the HIV-1 reverse transcriptase enzyme, which is essential for the replication of the virus, as described in research published in the Journal of Virology and the Proceedings of the National Academy of Sciences. This enzyme is responsible for converting the viral RNA genome into DNA, which can then be integrated into the host cell's genome, a process that has been studied in detail by researchers at the National Cancer Institute and the University of Oxford. By inhibiting this enzyme, efavirenz prevents the virus from replicating, thereby reducing the viral load in the body, as measured by techniques such as polymerase chain reaction and enzyme-linked immunosorbent assay, which have been developed by companies such as Roche Diagnostics and Abbott Laboratories.

● Medical_uses

efavirenz is used in combination with other antiretroviral drugs to treat HIV-1 infection, as recommended by the World Health Organization and the Centers for Disease Control and Prevention. It is often used in combination with tenofovir and emtricitabine, as part of a regimen known as Atripla, which is manufactured by Gilead Sciences and Bristol-Myers Squibb. The use of efavirenz has been endorsed by UNAIDS, the Joint United Nations Programme on HIV/AIDS, and the National Institutes of Health, and has been studied in clinical trials such as the 2NN Study and the Duet Study, which were conducted by researchers at institutions such as the University of California, Los Angeles and the University of Washington.

● Side_effects

The use of efavirenz can cause a range of side effects, including dizziness, headache, and nausea, as reported in studies published in the Journal of Acquired Immune Deficiency Syndromes and the AIDS Research and Human Retroviruses. More serious side effects can include seizures, depression, and suicidal thoughts, which have been studied by researchers at institutions such as the National Institute of Mental Health and the University of California, San Diego. The risk of these side effects can be increased by the use of other medications, such as ritonavir and saquinavir, which are manufactured by companies such as Abbott Laboratories and Roche Holding.

● Pharmacology

The pharmacology of efavirenz involves the inhibition of the cytochrome P450 enzyme, which is responsible for the metabolism of many drugs, as described in research published in the Journal of Pharmacology and Experimental Therapeutics and the European Journal of Clinical Pharmacology. This can lead to interactions with other medications, such as warfarin and phenytoin, which are manufactured by companies such as Bristol-Myers Squibb and Pfizer. The pharmacokinetics of efavirenz have been studied in detail by researchers at institutions such as the University of Michigan and the University of North Carolina at Chapel Hill, and have been influenced by the work of scientists such as Gertrude Elion and George Hitchings.

● History

The development of efavirenz was supported by research conducted at institutions such as the University of California, San Francisco and the Massachusetts Institute of Technology, and was influenced by the work of scientists such as David Ho and Eric Lander. The first clinical trials of efavirenz were conducted in the late 1990s, and the drug was approved by the US Food and Drug Administration in 1998, as part of a regulatory process that involved the European Medicines Agency and the World Health Organization. Since then, efavirenz has become a key component of antiretroviral therapy regimens, as recommended by the European AIDS Clinical Society and the International AIDS Society, and has been used to treat millions of people with HIV/AIDS around the world, including in countries such as South Africa and India, where it has been distributed by organizations such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Bill and Melinda Gates Foundation. Category:Antiretroviral drugs